David Malcom Rodman sold $9.3M of Mineralys Therapeutics (MLYS)

Executed Jan 2, disclosed Jan 6, 4 days later.

Value, as filed

$9.3M

262,752 sh across 3 lots

Executed

Jan 2

the trade date, as filed

Disclosed

Jan 6

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

DR David Malcom Rodman Chief Medical Officer profile →

David Malcom Rodman (Chief Medical Officer) filed 11 Form 4 reports in the trailing twelve months (0 purchases, 11 sales), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $9.3M of MLYS (262,752 sh across 3 lots, as filed), executed Jan 2.

The name

MLYS Mineralys Therapeutics, Inc. MLYS · Healthcare · 50 filings in 24 months ticker →

Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by David Malcom Rodman in MLYS

MLYSSALE Mineralys Therapeutics, Inc. $557K
20,407 sh across 2 lots
Exec Jul 13
Filed Jul 15 · 8:58 PM ET MLYSSALE Mineralys Therapeutics, Inc. $350K
14,474 sh across 2 lots
Exec Jun 15
Filed Jun 17 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $152K
6,349 sh × $23.93
Exec Jun 12
Filed Jun 12 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $588K
20,404 sh across 2 lots
Exec May 12
Filed May 13 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $549K
20,406 sh across 2 lots
Exec Apr 13
Filed Apr 15 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $452K
17,074 sh across 2 lots
Exec Mar 12
Filed Mar 16 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $458K
16,342 sh across 3 lots
Exec Feb 12
Filed Feb 13 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. $623K
19,076 sh across 2 lots
Exec Jan 13
Filed Jan 15 · 5:30 PM ET